Afluria

• CMS NADAC weekly file (pharmacy acquisition, per unit)
• CMS Part B ASP quarterly payment limit file + NDC–HCPCS crosswalk
• CMS Maximum Fair Prices (IRA negotiated), matched on the NDC-9
• CMS Part D Spending by Drug (annual, name-matched, gross incl. dispensing fee)
• CMS Part D plan formulary/pricing files (SPUF): point-of-sale price across plans
• VA FSS / Big4 federal contract prices (per package; per unit when the package is a count above 1)
• CMS Federal Upper Limits + weighted AMP for the multiple-source drug group (monthly)
• Texas DSHS annual WAC catalog, then Texas/California increase filings (per package)

Each rung is the newest figure for this NDC from one price system, shown with its own unit — units differ, so compare a rung over time, not rung against rung. Part B is the file's payment limit (typically ASP+6%, WAC+3% for new drugs; sequestration is applied at claim level); when the NDC maps to several HCPCS codes the lowest code is shown and the count noted. Part D average is shown only on an exact brand-name match or a generic name with a single CMS row. FSS keeps the lowest active contract price, Big4 first, and skips 1¢ placeholders. The FUL belongs to the whole multiple-source group, so a brand NDC shows its generic group's ceiling. WAC is the Texas catalog's current list price, else the newest increase filing already in effect. To check a rung: open the named CMS/VA/state file for the date shown and find this NDC.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

• FDA Orange Book data files — patent and exclusivity tables for application BLA125254, edition retrieved 2026-08-24

Rows are the Orange Book's patent and exclusivity listings for this NDA, de-duplicated across product numbers (the file repeats a listing for every strength). A listed patent is a claim the sponsor filed; it may cover a use rather than the molecule, may be challenged, and may be delisted — a listing is not proof a generic is blocked. Pediatric extensions appear as *PED rows. FDA blocks automated downloads of the Orange Book from cloud servers, so the edition can trail FDA's monthly release; the retrieval date above is the edition shown. To check: search the application number on FDA's Orange Book site.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

• FDA NDC Directory (openFDA), read daily since 2026-07-15 — labeler_name per package
• DailyMed SPL establishment roles + name patterns → derived.labeler_kinds (repackager / manufacturer / unknown)

One row per labeler that lists any package with this exact generic-name string and dosage form; strengths are combined. 'First seen' is the first daily snapshot that contained the labeler here (2026-07-15 for everything present at the start), 'last seen' the most recent; a labeler counts as active when seen in the last 30 days. Repackagers and relabelers are flagged when their own labels show only repack/relabel operations or their name matches a known repackager, and are excluded from every 'makers' count on this page. Listing is not volume: a labeler with a listed NDC may ship little or nothing. To check: search the generic name in FDA's NDC Directory and list the labelers.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.